查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1935709

Macitentan锭剂市场按患者类型、适应症、治疗类型、剂量强度、品牌类型、最终用户和分销管道划分，全球预测，2026-2032年

Macitentan Tablets Market by Patient Type, Indication, Therapy Type, Dosage Strength, Brand Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Macitentan锭剂市场价值将达到 12 亿美元，到 2026 年将成长至 12.8 亿美元，到 2032 年将达到 18.8 亿美元，复合年增长率为 6.57%。

主要市场统计数据
基准年 2025 12亿美元
预计年份：2026年 12.8亿美元
预测年份：2032年 18.8亿美元
复合年增长率 (%) 6.57%

权威地介绍了现代Macitentan片剂环境的临床概况、相关人员影响和实际考量

Macitentan已成为治疗肺动脉高压的核心治疗选择之一，其独特的内皮素受体调节药理特性使其脱颖而出。本执行摘要阐述了影响Macitentan锭剂市场格局的临床、商业性和营运因素，重点分析了治疗模式、监管趋势和供应链因素如何共同影响药物的可及性和应用。

近期临床创新、监管演变和分销现代化如何重塑Macitentan疗法的交付方式和商业性定位？

在临床创新、监管调整以及优先考虑门诊和居家医疗的新型给药模式的共同推动下，Macitentan片剂市场正经历着变革性的变化。联合治疗的进步和对个人化治疗日益重视正在改变临床医生的决策流程，促使他们在某些患者群体中更早启动双重或多重用药策略。这些临床转变与肺血管疾病亚型诊断准确性的提高相辅相成，从而改变了治疗性介入的时机和强度。

评估美国关税调整对供应链、采购和定价造成的累积压力及其对Macitentan取得的影响

计划于2025年实施的新关税措施和贸易政策调整将对Macitentan片剂的供应链、采购经济效益以及整个治疗生态系统的定价产生重大影响。药品原料、製剂和包装材料的关税调整将增加製造商和下游经销商的到岸成本，迫使他们重新评估其筹资策略、製造地和库存管理实践。

全面的細項分析揭示了患者群体、临床适应症、治疗方法、剂型、品牌趋势和分销管道如何影响Macitentan的使用。

基于患者类型、适应症、治疗方法类型、剂量强度、品牌地位、最终用户和分销管道的详细細項分析，揭示了Macitentan坦片剂需求和使用情况的细微驱动因素。按患者类型分類的市场研究涵盖成人和儿童人群，检验了每种人群独特的临床监测要求和给药注意事项，这些因素会影响製剂的可接受性和依从性支持需求。按适应症分類的分析检视了结缔组织疾病相关性肺动脉高压、特发性肺动脉高压和分流相关性肺动脉高压的市场。每种适应症的进展模式、合併症负担和伴随用药情况各不相同，这些因素都会影响临床决策。

区域医疗保健系统、监管差异和分销能力将如何决定Macitentan片剂市场的准入管道并影响其策略优先顺序？

区域趋势将对Macitentan锭剂的可近性、监管方式和分销网络发展产生重大影响。美洲各地的医疗保健系统各不相同，从高度整合的私人保险模式到强调成本控制的公共项目，这些差异会影响合约策略、报销管道和患者负担能力策略。主要都市区专科肺科中心和强大的临床网络的普及支持集中实施，而遍远地区的用药仍然依赖远端医疗和专科药房推广计画。

策略性企业行动和伙伴关係模式将决定Macitentan锭产品组合的商业性永续性、差异化和市场准入结果。

Macitentan锭剂生产商之间的竞争，正日益体现在生命週期策略、伙伴关係模式和营运规模上，而非单纯的产品市场占有率。创新驱动型公司正透过强化临床差异化、拓展适应症以及完善病患支援体系来捍卫其高端市场地位。具体策略包括进行有针对性的研究者主导试验、提供可操作的真实世界证据项目，以及与专科药房合作，以简化患者治疗的启动和监测流程。

为确保Macitentan业务的持续成功，需采取综合方法，包括临床证据产生、供应链韧性以及有针对性的市场进入策略。

希望加强Macitentan业务的产业领导者应采取整合临床差异化、供应链韧性和市场进入洞察的策略。首先，他们应投资于真实世界证据项目，记录不同适应症和患者类型的治疗结果，从而为支付者和临床医生提供更强有力的价值提案。这些证据倡议应着重解决成人和儿童族群的依从性、长期安全性和疗效比较问题，以降低支付方的不确定性并支持差异化合约。

采用透明的多源资讯来源调查方法，结合专家访谈和二手临床及行业数据，以检验市场和临床洞察。

本执行摘要的研究整合了多来源证据、系统性的专家参与和反覆检验，以确保其准确性和实用性。主要研究内容包括对肺血管疾病专科临床医生、负责配发先进疗法的专科药剂师、医院采购负责人以及监管事务专家进行深度访谈，这些专家提供了有关核准和报销机制的背景资讯。这些定性研究结果与来自临床试验註册库、同行评审文献、监管申报文件和分销数据的二手资讯进行三角验证，从而绘製出供应链和分销模式图。

在Macitentan治疗中，临床、运作和可近性等关键要素的整合对于持续创造价值和患者治疗的连续性至关重要。

总之，Macitentan坦锭在肺动脉高压的治疗中占据战略地位，其特点是临床实践不断发展、分销管道现代化以及对价值论证的日益重视。患者细分、适应症特异性治疗管道以及不断变化的区域准入趋势的交汇，为产品生命週期中的各相关人员带来了机会和挑战。应对这些趋势需要协调投资于实证医学、供应链柔软性以及与支付方、医疗服务提供者和患者需求相符的有针对性的市场进入措施。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 依患者类型分類的Macitentan锭市场

  • 成人
  • 儿童

第九章Macitentan锭剂市场（依适应症划分）

  • 结缔组织疾病相关性肺动脉高血压
  • 特发性肺动脉高血压
  • 分流相关性肺动脉高血压

第十章Macitentan锭剂市场依治疗类型划分

  • 联合治疗
  • 单药治疗

第十一章Macitentan锭剂市场依剂量强度划分

  • 10mg
  • 5mg

第十二章Macitentan坦锭剂市场（依品牌类型划分）

  • 品牌Macitentan
  • 非专利Macitentan替坦

第十三章Macitentan坦锭剂市场：依最终用户划分

  • 门诊治疗中心
  • 医院
  • 专科诊所

第十四章Macitentan坦锭剂市场依通路划分

  • 离线频道
    • 医院药房
    • 零售药房
  • 网路药房

第十五章 各地区Macitentan锭剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章Macitentan坦锭剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国Macitentan锭剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 美国Macitentan锭剂市场

第十九章 中国Macitentan锭剂市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actelion Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila
Product Code: MRR-9A6A6F2974CA

The Macitentan Tablets Market was valued at USD 1.20 billion in 2025 and is projected to grow to USD 1.28 billion in 2026, with a CAGR of 6.57%, reaching USD 1.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.20 billion
Estimated Year [2026] USD 1.28 billion
Forecast Year [2032] USD 1.88 billion
CAGR (%) 6.57%

An authoritative introduction to the clinical profile, stakeholder implications, and practical considerations shaping the contemporary macitentan tablet environment

Macitentan has emerged as a central therapeutic option in the management of pulmonary arterial hypertension, bringing a distinct pharmacological profile to bear on endothelin receptor modulation. This executive summary introduces the clinical, commercial, and operational considerations that shape the macitentan tablet landscape, highlighting how treatment paradigms, regulatory dynamics, and supply chain forces converge to influence access and adoption.

The initial portion of this analysis situates macitentan within the broader therapeutic class by synthesizing clinical efficacy and safety observations alongside real-world usage patterns. It distinguishes patient cohorts by age and clinical presentation, and connects these patient-level dynamics to prescribing behavior among specialty clinicians. Moreover, it frames the evolving payer, hospital, and pharmacy responses that mediate uptake and adherence.

In framing the report, emphasis is placed on cross-functional implications for manufacturers, distributors, and providers. By examining clinical evidence, product differentiation, and distribution mechanics in tandem, this introduction provides readers with a cohesive lens through which to interpret subsequent sections. The result is a pragmatic, evidence-based foundation that prepares stakeholders to evaluate strategy options with clarity and confidence.

How recent clinical innovations, regulatory evolution, and distribution modernisation are reshaping macitentan therapy delivery and commercial positioning

The macitentan landscape is undergoing transformative shifts driven by converging clinical innovations, regulatory recalibrations, and changing delivery models that prioritize outpatient and home-based care. Advances in combination regimens and an increasing emphasis on personalized therapy have altered clinician decision pathways, prompting earlier initiation of dual or multi-drug strategies in select patient populations. These clinical shifts are complemented by enhancements in diagnostic acuity that identify pulmonary vascular disease subtypes sooner, thereby changing the timing and intensity of treatment interventions.

Concurrently, regulatory pathways in major jurisdictions are evolving to accommodate lifecycle management through label expansions and novel evidence packages, which in turn shape commercial strategies for differentiated formulations and dosing options. On the distribution side, digital pharmacy channels and integrated specialty pharmacy services are gaining prominence, requiring manufacturers to rethink patient support, adherence programs, and fulfillment logistics. Supply chain optimization and risk mitigation have moved to the foreground as manufacturers balance resilience with cost pressures, adopting dual-sourcing for active pharmaceutical ingredients and closer supplier oversight.

Collectively, these transformative forces create new opportunities for targeted clinical trials, value-based contracting, and differentiated patient engagement models. For stakeholders, the imperative is to align R&D, market access, and commercial operations so that clinical innovation translates into sustainable patient access and long-term portfolio resilience.

Assessing the cumulative supply chain, procurement, and pricing pressures stemming from United States tariff policy adjustments and their implications for macitentan access

The introduction of new tariff measures and trade policy shifts projected for the United States in 2025 has important implications for the macitentan tablet supply chain, procurement economics, and pricing dynamics across the therapeutic ecosystem. Tariff adjustments on pharmaceutical inputs, finished dosage forms, or packaging components can increase landed costs for manufacturers and downstream distributors, creating pressure to re-evaluate sourcing strategies, manufacturing footprints, and inventory management practices.

In response to potential tariff-driven cost increases, manufacturers may accelerate domestic manufacturing investments, transfer production lines to tariff-safe jurisdictions, or renegotiate supplier contracts to preserve margins while maintaining continuity of supply. These strategic moves can introduce lead time variability and transitional capacity constraints that require close coordination with providers and specialty pharmacies. Payers and hospital procurement teams may also adjust formulary decisions in favor of therapeutically equivalent options that demonstrate lower acquisition volatility, thereby influencing prescribing patterns.

Additionally, tariff-related uncertainty can prompt more aggressive use of long-term contracts, hedging strategies, and collaborative procurement across integrated delivery networks. For innovators, the need to justify premium pricing intensifies, pushing manufacturers to reinforce evidence of differentiated clinical value and to pursue risk-sharing agreements where appropriate. Ultimately, the cumulative impact of tariff shifts is to magnify the importance of supply chain transparency, agile manufacturing, and value demonstration in preserving patient access to macitentan therapy.

Comprehensive segmentation analysis revealing how patient cohorts, clinical indications, therapies, dosage forms, brand dynamics, and distribution channels shape macitentan utilization

A granular segmentation lens reveals the nuanced drivers of demand and utilization for macitentan tablets when analyses are anchored to patient type, indication, therapy type, dosage strength, brand status, end user, and distribution channel. Based on Patient Type, the market is studied across Adult and Pediatric cohorts, each presenting distinct clinical monitoring requirements and dosing considerations that affect formulation acceptance and adherence support needs. Based on Indication, the market is studied across CTD Associated PAH, Idiopathic PAH, and Shunt Associated PAH, with each indication exhibiting different progression patterns, comorbidity burdens, and concomitant medication profiles that influence clinical decision-making.

When viewed through Therapy Type, the market is studied across Combination Therapy and Monotherapy, highlighting the growing role of concurrent agents in achieving optimal hemodynamic outcomes and the operational implications for dosing complexity and adverse event management. Based on Dosage Strength, the market is studied across 10 Mg and 5 Mg presentations, which shape prescribing flexibility and inventory segmentation across pharmacies and hospitals. Based on Brand Type, the market is studied across Branded Macitentan and Generic Macitentan, with brand equity, patent status, and bioequivalence considerations driving differentiated access strategies.

Finally, Based on End User, the market is studied across Ambulatory Care Centers, Hospitals, and Specialty Clinics, while Based on Distribution Channel, the market is studied across Offline Channels and Online Pharmacy, with Offline Channels further studied across Hospital Pharmacy and Retail Pharmacy. This multi-dimensional segmentation framework clarifies where clinical demand intersects with commercial pathways and where targeted interventions-such as adherence programs, clinician education, and formulary strategies-can most effectively influence outcomes.

How regional healthcare architectures, regulatory heterogeneity, and distribution capabilities determine access pathways and prioritise tailored macitentan market strategies

Regional dynamics exert material influence on macitentan tablet accessibility, regulatory approaches, and the configuration of distribution networks. In the Americas, healthcare systems vary from highly integrated private-payer models to public programs that emphasize cost containment, which affects contracting strategies, reimbursement pathways, and patient affordability measures. The prevalence of specialized pulmonary centers and robust clinical networks in major urban centers supports concentrated adoption, whereas rural access continues to rely on telemedicine and specialty pharmacy outreach programs.

In Europe, Middle East & Africa, heterogeneity in regulatory standards and reimbursement frameworks creates a patchwork of market entry considerations. Countries with centralized health technology assessment systems require compelling comparative effectiveness data and health economic dossiers, while other jurisdictions prioritize expedited access for orphan or high-need therapies. Distribution infrastructure differences and variable cold-chain capabilities influence inventory strategies, particularly for multi-dose regimens and hospital-centric dispensation.

In Asia-Pacific, the interplay of emerging middle-income markets and established high-income systems drives a dual focus on rapid access and cost containment. Local manufacturing initiatives and regional trade agreements shape supply pathways, while differential rates of specialty care development determine the pace of adoption. Across all regions, the common themes are the need for evidence of real-world effectiveness, tailored patient support solutions, and partnerships that bridge clinical, payer, and distribution stakeholder interests to expand appropriate access.

Strategic company behaviours and partnership models that determine commercial resilience, differentiation, and access outcomes for macitentan tablet portfolios

Competitive behavior among companies involved with macitentan tablets is increasingly defined by life cycle strategies, partnership models, and operational scale rather than simple product presence. Innovator-oriented firms focus on reinforcing clinical differentiation, pursuing label expansions, and strengthening patient support ecosystems to defend premium positioning. Their tactics include targeted investigator-sponsored studies, pragmatic real-world evidence programs, and collaborations with specialty pharmacies to streamline patient initiation and monitoring.

At the same time, generic entrants and specialty manufacturers concentrate on cost-efficient production, regulatory filings for bioequivalence, and rapid market entry tactics that leverage established distribution relationships. Contract manufacturing organizations and advanced formulation developers play a pivotal role by enabling capacity flexibility and by offering services that accelerate time-to-shelf for secondary suppliers. Across the competitive spectrum, supply chain reliability and quality certification remain critical differentiators that influence purchasing decisions by hospitals and pharmacies.

Partnerships between commercial stakeholders and clinical networks are also emerging as a decisive factor, enabling coordinated patient education, adherence tracking, and value articulation to payers. Companies that combine robust clinical evidence with operational excellence in distribution and patient services are positioned to capture the highest utility from the macitentan therapeutic class, while those that fail to invest in integrated post-launch support risk rapid erosion of uptake in competitive tendering and formulary evaluations.

Actionable strategic imperatives to combine clinical evidence generation, supply chain resilience, and targeted market access tactics for durable macitentan success

Industry leaders seeking to strengthen their macitentan franchises should pursue integrated strategies that combine clinical differentiation, supply chain resilience, and market access acumen. First, invest in real-world evidence programs that document outcomes across diverse indications and patient types, thereby enabling stronger value propositions to payers and clinicians. These evidence initiatives should be designed to address adherence, long-term safety, and comparative effectiveness in both adult and pediatric cohorts to reduce payer uncertainty and to support differentiated contracting.

Second, diversify manufacturing and sourcing strategies to mitigate tariff and geopolitical risk, including dual-sourcing of active pharmaceutical ingredients, nearshoring options, and strategic inventory buffers. By proactively addressing potential supply disruptions, companies can preserve continuity of care for patients dependent on chronic therapy. Third, tailor commercial deployment by aligning dosage strength availability, branded versus generic positioning, and pharmacy distribution models to the specific needs of ambulatory centers, hospitals, and specialty clinics. This nuanced approach improves patient initiation and reduces friction in the dispensing process.

Finally, enhance payer and provider engagement through outcome-aligned contracting, bundled care pilots, and targeted patient support programs that reduce administrative burden and optimize adherence. By operationalizing these recommendations, manufacturers and stakeholders can convert clinical advances into sustained patient access and commercial viability while navigating the complex policy and market shifts that define the current environment.

A transparent, multi-source research methodology combining primary expert interviews and secondary clinical and trade data to validate market and clinical insights

The research underpinning this executive summary integrates multi-source evidence, structured expert engagement, and iterative validation to ensure accuracy and practical relevance. Primary research components included in-depth interviews with clinicians specializing in pulmonary vascular disease, specialty pharmacists responsible for dispensing advanced therapies, hospital procurement officers, and regulatory affairs professionals who provided context on approval and reimbursement mechanisms. These qualitative insights were triangulated with secondary sources obtained from clinical trial registries, published peer-reviewed literature, regulatory submissions, and trade data to map supply chain and distribution patterns.

Analytical rigor was reinforced through a structured synthesis process that converted clinical findings into operational implications; for example, translating dosing variability into inventory segmentation needs across different end users. Data quality checks involved cross-verification of clinical outcomes with published study endpoints and confirmation of regulatory timelines against public filings. Where uncertainties remained, follow-up interviews and sensitivity reviews were conducted with domain experts to reconcile conflicting inputs and to highlight areas requiring further primary investigation.

Finally, the methodology emphasizes transparency and reproducibility by documenting data sources, interview protocols, and analytical assumptions. This approach allows stakeholders to assess the validity of insights, request targeted replications, and commission custom analyses that extend the core findings into specific geographies, patient subgroups, or commercial scenarios.

Conclusive synthesis of clinical, operational, and access imperatives that define durable value creation and patient continuity for macitentan therapies

In conclusion, macitentan tablets occupy a strategic position within pulmonary arterial hypertension management, characterized by evolving clinical practice, distribution modernisation, and increased emphasis on value demonstration. The intersection of patient segmentation, indication-specific treatment pathways, and shifting regional access dynamics creates both opportunities and risks for stakeholders across the product lifecycle. Addressing these dynamics requires coordinated investments in evidence generation, supply chain flexibility, and targeted market access initiatives that align with the needs of payers, providers, and patients.

Manufacturers and partners that anticipate tariff and trade disruptions, invest in local and regional manufacturing resilience, and commit to robust real-world data collection will be better positioned to sustain access while defending commercial value. At the same time, a focused approach to segmentation-attending to differences by patient type, indication, therapy modality, dosage strength, brand status, and distribution channel-will enable more efficient allocation of resources and more impactful interventions to improve adherence and outcomes.

Ultimately, the path to long-term success in the macitentan space rests on the ability to convert clinical promise into demonstrable value for healthcare systems, to ensure supply continuity for patients, and to craft commercially viable models that support innovation while maintaining affordability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Macitentan Tablets Market, by Patient Type

  • 8.1. Adult
  • 8.2. Pediatric

9. Macitentan Tablets Market, by Indication

  • 9.1. CTD Associated PAH
  • 9.2. Idiopathic PAH
  • 9.3. Shunt Associated PAH

10. Macitentan Tablets Market, by Therapy Type

  • 10.1. Combination Therapy
  • 10.2. Monotherapy

11. Macitentan Tablets Market, by Dosage Strength

  • 11.1. 10 Mg
  • 11.2. 5 Mg

12. Macitentan Tablets Market, by Brand Type

  • 12.1. Branded Macitentan
  • 12.2. Generic Macitentan

13. Macitentan Tablets Market, by End User

  • 13.1. Ambulatory Care Centers
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Macitentan Tablets Market, by Distribution Channel

  • 14.1. Offline Channels
    • 14.1.1. Hospital Pharmacy
    • 14.1.2. Retail Pharmacy
  • 14.2. Online Pharmacy

15. Macitentan Tablets Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Macitentan Tablets Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Macitentan Tablets Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Macitentan Tablets Market

19. China Macitentan Tablets Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Actelion Pharmaceuticals Ltd.
  • 20.6. Alembic Pharmaceuticals Limited
  • 20.7. Aurobindo Pharma Limited
  • 20.8. Cipla Limited
  • 20.9. Dr. Reddy's Laboratories Ltd.
  • 20.10. Glenmark Pharmaceuticals Ltd.
  • 20.11. Hetero Labs Limited
  • 20.12. Johnson & Johnson
  • 20.13. Lupin Limited
  • 20.14. Mylan N.V.
  • 20.15. Sun Pharmaceutical Industries Ltd.
  • 20.16. Torrent Pharmaceuticals Ltd.
  • 20.17. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MACITENTAN TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MACITENTAN TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY CTD ASSOCIATED PAH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY CTD ASSOCIATED PAH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY CTD ASSOCIATED PAH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY IDIOPATHIC PAH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY IDIOPATHIC PAH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY IDIOPATHIC PAH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SHUNT ASSOCIATED PAH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SHUNT ASSOCIATED PAH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SHUNT ASSOCIATED PAH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 10 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 10 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 10 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 5 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 5 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 5 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRANDED MACITENTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRANDED MACITENTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRANDED MACITENTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GENERIC MACITENTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GENERIC MACITENTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GENERIC MACITENTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GCC MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 179. G7 MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. G7 MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NATO MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 188. NATO MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)